In the phase 3 HER2CLIMB-02 trial, researchers evaluated the efficacy and safety of tucatinib plus T-DM1 compared to T-DM1 alone in HER2+ locally advanced or metastatic breast cancer.

One year of adjuvant trastuzumab emtansine (T-DM1) leads to an impressive 5-year invasive disease-free survival rate of 97% among women with stage I human epidermal growth factor receptor 2 ...

SAN ANTONIO – Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive ...

More than 92% of patients treated with Daiichi Sankyo and AstraZeneca’s ENHERTU were free of invasive disease at three years DESTINY-Breast05 presented in ESMO Presidential Symposium I alongside ...

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Follow-up results from the ATEMPT trial showed that ...

Patient undergoing chemotherapy. Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The ...

Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration ...

After reviewing the positive findings in HER2-positive early-stage breast cancer from both DESTINY-Breast11 (DB-11) and ...

Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support ENHERTU as the potential new standard of care in previously treated patients ...